During CKD, iron deficiency and chronic inflammation are two major factors contributing to hyporesponsiveness to erythropoietin treatment [8]. Inflammation, specifically through the increased production of hepcidin, plays a key role in this resistance by mediating iron sequestration. The gene discussed is HAMP; the disease is nutritional disorder.